Published: 4 August 2016
Author(s): Wail Nammas, Adam de Belder, Matti Niemelä, Jussi Sia, Hannu Romppanen, Mika Laine, Pasi P. Karjalainen
Issue: August 2016
Section: Original Article

The BASE ACS trial demonstrated an outcome of titanium–nitride–oxide-coated bioactive stents (BAS) that was non-inferior to everolimus-eluting stents (EES) in patients presenting with acute coronary syndrome (ACS). We performed a post hoc analysis of elderly versus non-elderly patients from the BASE ACS trial.

Newsletters

Stay informed on our latest news!